Hi @markeewan I continued the use of 20% of revenue simply because that was the example used by Mozzarc in the post I cross referenced my post to. But in addition to that, it makes sense to me that PAR will have to partner with a Big Pharma company to ramp up marketing and distribution and it’s a physical product so there will be costs involved in shipping, storage, insurance etc, etc... so no one involved in the process gets 100% of top line revenue.
Year 1 Revenue, page-18
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.005(2.00%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 23.5¢ | $105.4K | 437.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1325 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 29564 | 3 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |